Get the latest news alerts: at Twitter.

LTW and Wire Reports

RESEARCH TRIANGLE PARK, N.C. – and Southern California Permanente Medical Group (SCPMG) announced an agreement Tuesday to help accelerate the development of new and more effective medicines.

Southern California Permanente Medical Group will join Quintiles’ three other prime sites globally selected for their long-term commitment to clinical research. Clinical research professionals from both Quintiles and SCPMG will work together closely to enhance the productivity and quality of clinical research offered at the SCPMG site.

Biopharmaceutical companies sponsoring trials will benefit from greater collaboration between clinicians and research professionals, and robust processes for reducing complexity and accelerating trials.

Adam Chasse, Head of Global Prime Sites at Quintiles said the Durham-based biopharmaceutical services company undertakes more clinical research than any other organization, and that is why customers rely on Quintiles to help them navigate risk and seize opportunity in this landscape called “the new health.”

“It is therefore critical that we develop alliances with healthcare providers that share our focus on developing new and better medicines while keeping patient care at the forefront,” added Chasse. “Kaiser Permanente’s rich background in clinical, epidemiologic, and translational research is a natural fit with Quintiles’ core capabilities.”

Financial terms of the deal were not disclosed.

Quintiles three other prime sites are at the University of Pretoria in South Africa, Queen Mary’s College in London and the Washington Hospital Center in Washington D.C.